Brookline Capital Acquisition set a July 27 meeting for shareholders to vote on thre proposed merger with biopharmaceutical company Apexigen. The registration statement on the deal is now effective.
The transaction values Apexigen at a $205 million on a net-equity basis and includes a $15 million fully committed PIPE. Separate from the PIPE financing, Lincoln Park Capital Fund, Apexigen and Brookline have entered into a committed investment agreement under which the combined company would have the right to direct Lincoln Park Capital to purchase up to $50 million of common stock in the combined company over 24 months.
Apexigen is focused on discovering and developing a new generation of antibody therapeutics for oncology. Read more.
